TW202546008A - Her2標靶藥物 - Google Patents

Her2標靶藥物

Info

Publication number
TW202546008A
TW202546008A TW114129312A TW114129312A TW202546008A TW 202546008 A TW202546008 A TW 202546008A TW 114129312 A TW114129312 A TW 114129312A TW 114129312 A TW114129312 A TW 114129312A TW 202546008 A TW202546008 A TW 202546008A
Authority
TW
Taiwan
Prior art keywords
amino acid
antibody
acid sequence
sequence number
antigen
Prior art date
Application number
TW114129312A
Other languages
English (en)
Chinese (zh)
Inventor
加藤幸成
金子美華
中山大介
黑木雅禮
Original Assignee
日商小野藥品工業股份有限公司
國立大學法人東北大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商小野藥品工業股份有限公司, 國立大學法人東北大學 filed Critical 日商小野藥品工業股份有限公司
Publication of TW202546008A publication Critical patent/TW202546008A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW114129312A 2020-11-30 2021-11-29 Her2標靶藥物 TW202546008A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020-198044 2020-11-30
JP2020198044 2020-11-30
JP2021-110912 2021-07-02
JP2021110912 2021-07-02

Publications (1)

Publication Number Publication Date
TW202546008A true TW202546008A (zh) 2025-12-01

Family

ID=81754499

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114129312A TW202546008A (zh) 2020-11-30 2021-11-29 Her2標靶藥物
TW110144472A TW202229359A (zh) 2020-11-30 2021-11-29 Her2標靶藥物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110144472A TW202229359A (zh) 2020-11-30 2021-11-29 Her2標靶藥物

Country Status (10)

Country Link
US (2) US20240002531A1 (https=)
EP (1) EP4253420A4 (https=)
JP (2) JP7393774B2 (https=)
KR (1) KR20230114747A (https=)
AU (1) AU2021387127A1 (https=)
CA (1) CA3199473A1 (https=)
IL (1) IL303154A (https=)
MX (1) MX2023005864A (https=)
TW (2) TW202546008A (https=)
WO (1) WO2022114163A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3247010A1 (en) 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
EP4504914A4 (en) * 2022-04-08 2026-04-29 Fate Therapeutics Inc Cells having solid tumor targeting backbone and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
PT2330131E (pt) 2009-12-07 2015-01-14 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Anticorpos contra a variante truncada de her-2 ctf-611
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11851479B2 (en) * 2018-06-18 2023-12-26 Dxdiscovery, Inc. Methods and compositions for pertussis diagnosis
CA3247010A1 (en) * 2022-04-08 2023-10-12 Ono Pharmaceutical Co., Ltd. CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING

Also Published As

Publication number Publication date
IL303154A (en) 2023-07-01
MX2023005864A (es) 2023-06-05
EP4253420A1 (en) 2023-10-04
WO2022114163A1 (ja) 2022-06-02
KR20230114747A (ko) 2023-08-01
US11981747B1 (en) 2024-05-14
US20240002531A1 (en) 2024-01-04
TW202229359A (zh) 2022-08-01
JP7393774B2 (ja) 2023-12-07
AU2021387127A1 (en) 2023-06-22
JP2024020436A (ja) 2024-02-14
JPWO2022114163A1 (https=) 2022-06-02
CA3199473A1 (en) 2022-06-02
EP4253420A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
CN113227135B (zh) 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
CN109563169B (zh) 抗hla-g特异性抗体
CN106999576B (zh) 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
RS56219B1 (sr) Antitela protiv csf-1r
HK1199887A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody
WO2020026987A1 (ja) 抗ｒｏｒ１モノクローナル抗体およびその機能的断片、遺伝子、薬剤デリバリー組成物、並びに、医薬組成物
JP7324777B2 (ja) 腫瘍抗原に対するｌ２ａ５抗体またはその機能的断片
US20230365676A1 (en) Cd33 antibodies
CN115505043A (zh) 特异性结合糖基化ceacam5的抗体
CN117980332A (zh) 抗b7-h4/抗4-1bb双特异性抗体及其应用
TW202546008A (zh) Her2標靶藥物
WO2022175474A1 (en) Vegfa-binding molecules
CN107108734B (zh) 单克隆抗gpc-1抗体和其用途
WO2010119691A1 (ja) 抗tmprss11e抗体を用いた癌の診断と治療
EP4079758A1 (en) Semg2 antibody and use thereof
CN116615239A (zh) Her2靶向剂
HK40091222A (zh) Her2靶向剂
CN114907478A (zh) 结合lag-3的抗体及其用途
CN115838424A (zh) 靶向tigit的单克隆抗体
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN121464158A (zh) 抗Claudin18.2抗体及其制备和使用方法
WO2022213050A1 (en) Il-38-specific antibodies
CN121419996A (zh) 用于治疗受试者的her2低表达肿瘤的抗her2抗体
HK1149483B (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
HK1149483A1 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers